About this study
This is a research study for patients who have acute lymphoblastic leukemia (ALL) that has come back after treatment (relapsed). Researchers want to find out if two new drugs called venetoclax and navitoclax are safe and if they are beneficial for children, adolescents and young adults when combined with chemotherapy.
Venetoclax is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of leukemia in adults. Venetoclax is not approved by the FDA for treating childhood leukemia. Navitoclax is not approved by the FDA.
Purpose of this clinical trial
The main goal of this study is to find out the good and bad effects of treatment with venetoclax and navitoclax when given with chemotherapy to children with relapsed and refractory ALL.
Eligibility overview
Inclusion criteria include:
- Diagnosed with acute lymphoblastic leukemia or lymphoma that has come back
- Between 4 and 30 years old
- Weigh more than 20 kg (44.09 lbs.)
- Able to swallow pills
- Has not taken navitoclax in the past
- Fully recovered from effects of any earlier treatment
Exclusion criteria:
- HIV infection or active hepatitis B or C infection
- Pregnant or breastfeeding